Organs-on-chips Market by Type (Brain-on-a-chip, Heart-on-a-chip, Kidney-on-a-chip), Application (Drug Discovery, Physiological Model Development, Toxicology Research), End-user - Global Forecast 2024-2030

Organs-on-chips Market by Type (Brain-on-a-chip, Heart-on-a-chip, Kidney-on-a-chip), Application (Drug Discovery, Physiological Model Development, Toxicology Research), End-user - Global Forecast 2024-2030

The Organs-on-chips Market size was estimated at USD 119.50 million in 2023 and expected to reach USD 157.36 million in 2024, at a CAGR 33.92% to reach USD 923.59 million by 2030.

Organs-on-chips are microfluidic devices that simulate the physiological responses of organ systems in an in vitro setting. Organs-on-chips are composed of a transparent, flexible polymer; these chips contain microchannels lined with living cells and tissue that mimic the structure and function of full-sized organs. By replicating the biological and mechanical environment of human organs, these devices offer a sophisticated platform for disease modeling, drug testing, and personalized medicine while reducing the need for animal testing. The pressing need for more predictive and accurate models for drug discovery and safety testing boosts the importance of organs-on-chips models. Additionally, regulatory shifts towards reducing animal testing bolster the adoption of organs-on-chips models. However, the integration of organs-on-chips into mainstream research and industry impacts its adoption. Furthermore, technological advancements in microfluidics and 3D cell culture create substantial opportunities for organ-on-chips adoption.

Regional Insights

The American region, including the United States & Canada, is at the forefront of the organs-on-chips market, driven by strong research institutions, substantial investments, and supportive government initiatives. Customer needs in the American region focus on drug development efficiency and personalized medicine applications. The European Union has been a supportive environment for organs-on-chips technology, facilitated by funding initiatives. The focus in the European Union is on enhancing drug discovery and safety testing, reducing animal testing, and improving patient outcomes. There is a strong emphasis on regulatory considerations and ethical standards. The Middle East, though nascent in the organs-on-chips market, shows potential for growth. Investments in healthcare infrastructure and a burgeoning interest in advanced technologies suggest expanding opportunities, especially in academic and research institutions. In the APAC region, China, Japan & India are rapidly emerging as key regions in the organs-on-chips market, with significant investments in research and development. The government and private sector's emphasis on healthcare innovation has fueled the expansion of organ-on-chips technology, focusing on drug development and disease models.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Organs-on-chips Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Increasing focus on developing alternatives for animal testing models
Growing investment in personalized medicine and research initiatives for early detection of drug toxicity
Increasing need for development of multiple-organs-on-a-chip models

Market Restraints

Issues related to the incorporation of organs-on-chips technologies into existing workflows

Market Opportunities

Technological advancements in organs-on-chips model system
Emerging application of organs-on-chips in oncology research

Market Challenges

Biological and technological complexities of organs-on-chips models

Market Segmentation Analysis

Type: Ongoing advancements on brain-on-a-chip models for neurological disorders
Application: Emerging applications of organs-on-chips in physiological model development for the personalized medicine

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Organs-on-chips Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Organs-on-chips Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

German organ-on-chip specialist Dynamic42 raises Series A financing round to expand internationally

Dynamic42 GmbH, a German innovator specializing in organ-on-chip technology, has successfully secured a mid-seven-figure investment in a Series A funding round. Dynamic42 has consistently demonstrated the societal and economic benefits of its technology, including safer drugs, cost-effective drug development, and a viable alternative to animal testing.

Over Euro 3 Million for Organ-On-Chip Development

The Dutch Research Council (NWO) has reported a significant investment of approximately 22.7 million euros in seven groundbreaking projects aimed at enhancing scientific infrastructure. This includes an allocation of over 3 million euros to the University of Twente for the creation of the innovative Organ-on-Chip Development Centre. Organs-on-chips, which simulate miniaturized versions of human organs, serve as pivotal tools for evaluating the safety and efficacy of various substances, including food components and pharmaceuticals.

FDA expands organ-on-a-chip research collaboration

The US Food and Drug Administration (FDA) has augmented its collaborative efforts with CN Bio, a pioneer in the field of multi-organ microphysiological systems (MPS). This collaboration is focused on harnessing the innovative capabilities of the PhysioMimix Multi-organ System to refine the preclinical assessment of human drug bioavailability. This marks a significant step away from traditional animal model dependencies, which have been identified as inadequate due to physiological and metabolic discrepancies when predicting human responses.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Organs-on-chips Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Organs-on-chips Market, highlighting leading vendors and their innovative profiles. These include 4DCell, AlveoliX AG, AxoSim, Inc., Beonchip S. L., Bi/ond Solutions B.V., BICO Group AB, BiomimX S.r.l., Cherry Biotech, CN Bio Innovations Limited, Curi Bio, Inc., Dynamic42 GmbH, Elveflow, Emulate, Inc., Emulate, Inc. by UAMS, InSphero AG, Kirkstall Ltd., Micronit B.V., Mimetas B.V., NETRI SAS, Nortis Inc., SynVivo, Inc., The Charles Stark Draper Laboratory, Inc., TissUse GmbH, uFluidix, and Valo Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Organs-on-chips Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Brain-on-a-chip
Heart-on-a-chip
Kidney-on-a-chip
Lung-on-a-chip
Skin-on-a-chip
Application
Drug Discovery
Physiological Model Development
Toxicology Research
End-user
Academic & Research Institutes
Cosmetics Industry
Pharmaceutical & Biotechnology Companies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year